On Wednesday, when it is anticipated to make a decision regarding harsh new court-ordered restrictions on the widely used pill, the US Supreme Court will intervene in the bitter and emotive controversy over the abortion medicine mifepristone.
It positions the conservative-leaning bench for its biggest reproductive rights intervention since a landmark decision that denied American women the constitutional right to an abortion 10 months ago.

Since then, pro-life organizations have refocused their efforts on the FDA’s 2000 approval of the abortion drug mifepristone, which is now used in more than half of all abortions in the United States.

Those efforts bore fruit earlier this month when a federal judge said the FDA approval was flawed and the drug should be withdrawn.

The Supreme Court will have till midnight on Wednesday to make a decision after an appeals court rejected any ban on the drug but set tight access limits.

The temporary delays and multiple-level judgements have exacerbated the legal ambiguity and anxiety that individuals who oppose what they see as a complete assault on women’s reproductive rights are already experiencing.

Approximately two dozen states have either outlawed or severely restricted access to abortion after the Supreme Court overturned the defining Roe v. Wade decision, which had protected the constitutional right to abortion for fifty years.

Regulator confusion
According to Carrie Flaxman, senior director of public policy litigation at Planned Parenthood, a major abortion provider and advocacy group, the latest legal dispute over mifepristone has turned into a “judicial ping pong game.”

According to Flaxman, the back and forth is “creating chaos and confusion” and affecting access to “safe and effective medication.”

It is “untenable” for healthcare professionals and patients to “live day to day under these ever-changing rules and interpretations,” according to Ushma Upadhyay, a public health expert at the University of California, San Francisco.

The anti-abortion coalition that first initiated the action against the FDA reiterated their contentious assertions that the medicine was harmful in a brief to the court on Tuesday.

The FDA and the company that sells mifepristone, according to the group, “brazenly flouted the law and applicable regulations… and continually placed politics above women’s health.”

Even as conservative groups work to restrict or even outlaw the operation, polls consistently show that a large majority of Americans support access to safe abortion for as long as it is available.

Studies show that when mifepristone is administered, more than 95% of pregnancies are successfully terminated.

Serious consequences that necessitate medical attention, such as heavy bleeding, fever, infections, or allergic reactions, are uncommon.